Intensive LDL-C Targeting Enhances Clinical Outcomes in CVD: NEJM

These findings were published on March 28, 2026, in the New England Journal of Medicine.

The Clinical Challenge of Secondary Prevention

Effective management of lipids is a cornerstone of secondary prevention for individuals who have already experienced manifestations of atherosclerotic cardiovascular disease (ASCVD), such as heart attacks or strokes. While international clinical guidelines have increasingly recommended more aggressive targets for low-density lipoprotein (LDL) cholesterol, robust evidence from large-scale randomized trials comparing specific low-level targets remains surprisingly limited. Historically, the "lower is better" hypothesis has been supported by various observational studies, but the exact threshold for optimal secondary prevention—whether to aim for less than 70 mg per deciliter or to push even lower—has been a subject of ongoing debate among clinicians. The Ez-PAVE trial sought to address this gap by providing direct comparative data within a high-risk patient population.

Study Overview

The Ez-PAVE trial was an open-label superiority study conducted across multiple centers in South Korea. The researchers randomly assigned 3,048 adult patients with diagnosed atherosclerotic cardiovascular disease (ASCVD) in a 1:1 ratio to one of two treatment strategies: an intensive-targeting group (aiming for LDL cholesterol <55 mg per deciliter) or a conventional-targeting group (aiming for LDL cholesterol <70 mg per deciliter). The primary endpoint evaluated over three years was a composite measure of significant clinical outcomes, including death from cardiovascular (CV) causes, nonfatal myocardial infarction (MI), nonfatal stroke, any coronary or peripheral revascularization, or hospitalization required for unstable angina. Safety assessments were also integral to the study, monitoring for potential adverse effects associated with very low cholesterol levels.

The key findings from the study include:

• The median LDL cholesterol levels achieved during the trial were 56 mg per deciliter in the intensive group versus 66 mg per deciliter in the conventional group.

• A primary endpoint event occurred in 6.6% of patients in the intensive-targeting group (100 patients) compared to 9.7% in the conventional-targeting group (147 patients).

• The intensive strategy resulted in a hazard ratio (HR) of 0.67, representing a statistically significant 33% reduction in the risk of major adverse cardiovascular events (P=0.002).

• Safety profiles were generally comparable between groups; however, there was a notably lower incidence of creatinine elevation observed in the intensive-targeting cohort.

Clinical Relevance and Implementation

For practicing cardiologists and primary care physicians, the study provides strong evidence that a target of less than 55 mg per deciliter should be the standard of care for high-risk patients with atherosclerotic cardiovascular disease (ASCVD). Achieving these lower levels resulted in a clear, 3.1% absolute reduction in the cumulative incidence of major cardiovascular events over just three years. The fact that safety outcomes, including renal function (indicated by creatinine levels), were either similar or improved in the intensive group should alleviate concerns regarding the potential toxicity of aggressive lipid-lowering therapy. Moving forward, clinicians should prioritize the use of potent statins and non-statin therapies to reach these more stringent targets, ensuring that patient management aligns with the latest evidence for maximizing cardiovascular protection.

Reference:

Lee YJ, Lee SJ, Kim JW, et al. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease. New England Journal of Medicine. 2026 Mar 28.